Revelation (REVB) news
Recent news
Revelation Biosciences - Phase 2/3 Titan study expected to begin later this year
Revelation Biosciences, Inc. (NASDAQ: REVB) is preparing to initiate its Phase 2/3 Titan study later in 2026, following the successful completion of its PRIME Phase 1b clinical trial in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The PRIME study, which concluded in July 2025,…
AInvest Wire · Aug 19, 2026Optronics Systems - Karen Hawkins to resign as CFO and secretary effective December 31, 2026 - SEC filing
Optex Systems Holdings Inc. has announced that Karen Hawkins will resign from her roles as Chief Financial Officer and Secretary of the company, effective December 31, 2026, as disclosed in a recent SEC filing . The resignation follows a routine executive transition and is not attributed to any…
AInvest Wire · Jun 17, 2026Lucid Group, Inc. investors have until July 28, 2026 to seek lead plaintiff role
Lucid Group, Inc. (NASDAQ: LCID) investors who purchased the company’s securities between February 25, 2026, and April 13, 2026, have until July 28, 2026, to seek the lead plaintiff role in a pending securities class action lawsuit. The lawsuit alleges that Lucid made false or misleading statements…
AInvest Wire · Jun 12, 2026Raffles Interior - alleges actual price for 51% stake was HK$63.6 mln with HK$30 mln undisclosed
Raffles Interior (SEHK: 0362) has alleged that the actual price for a 51% stake in the company was HK$63.6 million, with HK$30 million of the amount reportedly undisclosed. This revelation comes amid ongoing scrutiny of the transaction, which has raised questions about transparency and valuation…
AInvest Wire · Jun 11, 2026JHX James Hardie to defend class action
James Hardie Industries plc (NYSE: JHX) is currently facing a securities fraud investigation and class action lawsuit from investors who purchased the company’s common stock or American Depositary Shares during the May 20, 2025, through August . The lawsuit, led by national plaintiffs’ firm Berger…
AInvest Wire · Jun 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.